Late-onset vaccine-induced immune thombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis

M Saleh, J Zimmermann, NC Lehnen, B Pötzsch… - Journal of Stroke and …, 2022 - Elsevier
M Saleh, J Zimmermann, NC Lehnen, B Pötzsch, JM Weller
Journal of Stroke and Cerebrovascular Diseases, 2022Elsevier
Objectives Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare complication after
adenoviral vector vaccination against COVID-19 reported up to 24 days after ChAdOx1
nCOV-19 (AZD1222) vaccination. This report describes a case with a significantly later onset
of VITT with cerebral venous sinus thrombosis. Case description We report a 42-year-old
woman presenting to the emergency department 53 days after AZD1222 vaccination with
sudden onset sensory aphasia and an 18-day history of headache. Cranial computed …
Objectives
Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare complication after adenoviral vector vaccination against COVID-19 reported up to 24 days after ChAdOx1 nCOV-19 (AZD1222) vaccination. This report describes a case with a significantly later onset of VITT with cerebral venous sinus thrombosis.
Case description
We report a 42-year-old woman presenting to the emergency department 53 days after AZD1222 vaccination with sudden onset sensory aphasia and an 18-day history of headache. Cranial computed tomography (CT) showed acute intracranial hemorrhage and CT venogram demonstrated thrombosis of the left vein of Labbé and transverse and sigmoid sinus. D-dimers were elevated and despite a normal platelet count, platelet-activating anti-PF4 antibody testing was positive, confirming the diagnosis of VITT. The patient was treated with intravenous immunoglobulins and argatroban, and was discharged without any neurological deficit on day 12.
Conclusion
Our report of VITT with symptom onset on day 35 and diagnosis of cerebral sinuous thrombosis on day 53 after AZD1222 vaccination significantly enhances the time window during which VITT may occur.
Elsevier